Pei Y, Lou X, Li K, et al. - In this study with 119 NSCLC patients and 74 age-matched healthy controls, researchers determined if leukocyte N6-methyladenosine (m6A) can serve as a novel biomarker for non-small-cell lung cancer (NSCLC). They collected peripheral blood from participants, from which total RNA was isolated from leukocytes for m6A measurement. In NSCLC patients vs healthy controls, significantly increased leukocyte m6A was found. In ROC curve analysis, a significant ability to differentiate lung adenocarcinoma and lung squamous cell carcinoma (LUSC) cases from healthy persons was enabled by leukocyte m6A. Compared with squamous cell carcinoma antigen and cytokeratin fragment 211, a superior sensitivity (100%) as well as specificity (85.7%) for LUSC was shown by m6A. Based on these findings, leukocyte m6A was concluded to be a potential noninvasive biomarker for NSCLC screening, monitoring, as well as diagnosis.